FDA Status of Red Light Therapy Devices

“FDA-approved red light therapy” is one of the most commonly misused phrases in consumer health marketing. The distinction between FDA clearance and FDA approval is not semantic — it represents fundamentally different regulatory pathways with different evidence requirements. Understanding this distinction is essential for evaluating device claims and making informed purchasing decisions.

This guide covers how the US Food and Drug Administration regulates photobiomodulation (PBM) devices, what 510(k) clearance actually means, how international regulatory bodies (EU, UK) approach the same question, and why most marketing claims about FDA status are misleading.

FDA Clearance vs FDA Approval — The Critical Difference

FDA Approval (Premarket Approval / PMA)

FDA approval via the Premarket Approval (PMA) pathway is the most rigorous regulatory process. It is required for Class III medical devices — those that support or sustain human life, are of substantial importance in preventing impairment of health, or present a potentially unreasonable risk of illness or injury.

PMA requires:

Full clinical trial data demonstrating both safety and efficacy
Extensive manufacturing and quality system documentation
Post-market surveillance requirements
Typical timeline: 1–3 years, cost: $250,000–$1M+

Examples of PMA-approved devices include pacemakers, cochlear implants, and breast implants. No consumer red light therapy panel has received PMA approval. When a company claims their device is “FDA-approved,” they are almost certainly using the term incorrectly.

FDA Clearance (510(k) Pathway)

FDA clearance via the 510(k) pathway is a substantially less rigorous process. It is used for Class I and Class II medical devices that can demonstrate “substantial equivalence” to a device already legally marketed in the US (a “predicate device”).

510(k) clearance requires:

Demonstration that the device is substantially equivalent to an existing predicate device
Safety testing data (biocompatibility, electrical safety, electromagnetic compatibility)
Does NOT require clinical trials demonstrating efficacy
Typical timeline: 3–12 months, cost: $5,000–$50,000

This is the pathway most red light therapy devices use. A 510(k)-cleared device has been reviewed for safety — it will not electrocute you, catch fire, or emit dangerous levels of radiation under normal use. It has not been proven to treat, cure, or prevent any specific medical condition.

What This Means in Practice

When a red light therapy company says their device is “FDA-cleared,” they are telling you:

The device has passed basic safety testing
It is substantially equivalent to another device already on the US market
The FDA has not evaluated whether the device actually works for any specific therapeutic purpose

This is important context. FDA clearance is a baseline safety credential, not a stamp of therapeutic efficacy.

Red Light Therapy Device Classifications

The FDA classifies medical devices into three tiers based on risk:

Class I — Low Risk

General controls only (labelling, manufacturing standards). Most consumer wellness devices fall here. Class I devices are often exempt from 510(k) requirements entirely. Some basic LED light therapy devices marketed for “general wellness” purposes may fall into this category, avoiding the 510(k) process altogether.

Class II — Moderate Risk

General controls plus special controls (performance standards, post-market surveillance). This is where most therapeutic red light therapy devices are classified. The relevant FDA product codes include:

Product Code ILY — “Lamp, Infrared, Therapeutic” — used for heating and pain relief applications
Product Code OQC — “Light Emitting Diode (LED), Photodynamic Therapy” — used for phototherapy applications
Product Code QEB — “Lamp, Ultraviolet, Dermatological” — used for certain skin therapy applications (primarily UV, but some red/NIR devices reference this)

Most consumer red light therapy panels that pursue FDA clearance are classified under Product Code ILY or OQC as Class II devices.

Class III — High Risk

Premarket Approval required. No consumer PBM devices fall into this category.

FDA-Cleared Red Light Therapy Devices

Several red light therapy devices have received FDA 510(k) clearance. Notable examples include:

Hair Growth Devices

Hair growth devices represent the strongest intersection of FDA clearance and clinical evidence in the PBM space. Several devices have been cleared specifically for the treatment of androgenetic alopecia:

HairMax LaserComb — One of the first LLLT devices to receive 510(k) clearance for hair growth (K101115, 2011). HairMax has conducted manufacturer-sponsored clinical trials showing increased hair density.
iRestore Laser Hair Growth System — 510(k) cleared for hair loss treatment
Capillus Laser Cap — 510(k) cleared, with supporting clinical trial data
Kiierr Laser Cap — 510(k) cleared for the treatment of androgenetic alopecia
Theradome LH80 PRO — 510(k) cleared laser hair growth helmet

These devices are cleared under FDA product codes specific to hair growth applications, and several have manufacturer-funded clinical trials supporting their claims. However, “cleared” still means the FDA reviewed safety and substantial equivalence — not that it independently verified the clinical trial results.

Pain and Inflammation Devices

Several professional-grade PBM devices have received 510(k) clearance for pain management and inflammation:

Erchonia FX 635 — One of the few laser therapy devices with specific FDA clearance for chronic low back pain. Erchonia has conducted multiple randomised controlled trials.
Thor Photomedicine — 510(k) cleared for a range of clinical applications including oral mucositis prevention
Celluma LED panels — 510(k) cleared for pain management, wrinkles, and acne (multiple clearances under different product codes)
LightStim — 510(k) cleared for wrinkles and pain management

Skin Treatment Devices

Omnilux — 510(k) cleared for acne treatment (blue light) and wrinkle reduction (red light). Omnilux has published peer-reviewed clinical data supporting their devices.
Celluma — Multiple 510(k) clearances covering acne, pain, and wrinkle reduction
DPL (LED Technologies) — 510(k) cleared for wrinkle treatment

Full-Body Consumer Panels

Most full-body consumer panels (Joovv, Mito Red, PlatinumLED, Bestqool, etc.) are marketed as “general wellness” devices rather than pursuing 510(k) clearance for specific medical claims. This is a deliberate regulatory strategy:

Without 510(k) clearance, manufacturers cannot make specific medical claims (“treats arthritis,” “heals wounds”) but can make general wellness claims (“supports muscle recovery,” “promotes skin health”)
With 510(k) clearance, manufacturers can make specific claims but must comply with FDA post-market surveillance, adverse event reporting, and Good Manufacturing Practice (GMP) requirements — significantly increasing compliance costs

Many consumer brands calculate that the marketing benefit of 510(k) clearance does not justify the regulatory burden, particularly when their devices are positioned as wellness products rather than medical devices.

Searching the FDA 510(k) Database

You can verify any FDA clearance claim yourself using the FDA 510(k) Premarket Notification Database.

To search:

Enter the manufacturer name (e.g., “HairMax,” “Erchonia,” “BioPhotas” for Celluma)
Or search by product code (ILY for infrared therapeutic lamps, OQC for LED phototherapy)
Each cleared device has a 510(k) number (e.g., K101115) that links to the clearance summary

If a company claims FDA clearance but you cannot find their device in this database, the claim may be false. This is not hypothetical — the FTC has taken action against companies making fraudulent FDA status claims for light therapy products.

EU Regulation: MDR and CE Marking

In the European Union, medical devices are regulated under the Medical Device Regulation (EU) 2017/745 (MDR), which replaced the older Medical Device Directive (MDD) in May 2021.

CE Marking

CE marking indicates that a device meets EU safety, health, and environmental protection requirements. For medical devices, CE marking requires:

Classification (Class I, IIa, IIb, or III)
Conformity assessment by a Notified Body (for Class IIa and above)
Clinical evaluation demonstrating safety and performance
Post-market surveillance system
Unique Device Identification (UDI)

Most therapeutic red light therapy devices sold in the EU would be classified as Class IIa medical devices, requiring assessment by a Notified Body.

Important Nuances

CE marking for a product as a “general electrical appliance” (under the Low Voltage Directive) is not the same as CE marking as a medical device (under the MDR). Some red light therapy companies display CE marks obtained under general product safety directives rather than medical device regulations. The distinction matters:

CE mark under LVD = the device meets general electrical safety standards (will not electrocute or burn you)
CE mark under MDR = the device meets medical device safety and performance requirements

Always check which directive the CE marking covers. A genuine MDR CE mark will include a four-digit Notified Body number.

UK MHRA Position

Following Brexit, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) regulates medical devices independently of the EU. As of 2026:

Devices with valid EU CE marks are accepted in the UK under transitional arrangements (extended through 2028 for most device classes)
The UK is implementing its own UKCA (UK Conformity Assessed) marking system
The MHRA takes a similar classification approach to the EU — therapeutic PBM devices would typically be Class IIa

The MHRA has not issued specific guidance on consumer red light therapy panels. Most consumer devices sold in the UK are marketed as wellness products rather than registered medical devices, similar to the regulatory approach in the US market.

UK Advertising Standards

The Advertising Standards Authority (ASA) actively enforces rules on health claims for consumer devices in the UK. Red light therapy companies selling to UK consumers must:

Not make specific medical claims without adequate evidence
Not reference “FDA approval” in UK marketing (the FDA is not relevant to UK regulation)
Distinguish between general wellness claims and therapeutic claims
Hold evidence to substantiate any health-related claims before making them

The ASA has upheld complaints against health device companies for making unsupported claims, and UK consumers can report potentially misleading marketing to the ASA.

Why “FDA-Approved” Claims Are Usually Misleading

When evaluating any red light therapy device marketed as “FDA-approved,” consider:

The term is almost certainly incorrect. The proper term for Class II devices is “FDA-cleared,” not “FDA-approved.” Companies that use the wrong term either do not understand the regulatory framework or are deliberately inflating their credentials.
Clearance covers safety, not efficacy. A 510(k)-cleared device has passed basic safety testing. The FDA has not verified that it works for any specific condition.
“General wellness” devices may not hold any FDA clearance at all. Many consumer panels are sold as general wellness products, which may not require 510(k) clearance. The company may be referencing a competitor’s clearance, their supplier’s clearance, or simply making a false claim.
The clearance may not cover the claimed use. A device cleared for “temporary relief of minor pain” cannot legally claim to treat hair loss based on the same clearance. Each therapeutic indication requires separate review.
International sellers using “FDA” credibility. Companies selling to UK or European markets may reference FDA status because it sounds authoritative, even though the FDA has no jurisdiction outside the United States. A UK buyer should look for CE marking under the MDR or UKCA marking.

What Actually Matters More Than FDA Status

For consumers evaluating red light therapy devices, the following factors are more meaningful than regulatory status:

Published Clinical Evidence

Does peer-reviewed research (not manufacturer marketing) support the use of the device’s wavelengths and power output for your target condition? The PBM literature contains thousands of studies — check PubMed for evidence specific to your needs.

Wavelength Accuracy

Does the device deliver the wavelengths it claims? The two most-studied wavelengths are 660 nm (red, superficial tissue) and 850 nm (near-infrared, deeper tissue). Reputable manufacturers provide spectral output data or third-party testing results.

Irradiance at Treatment Distance

What is the actual power density at a realistic treatment distance (15–20 cm), not at the surface? The therapeutic window identified in the PBM literature is approximately 10–100 mW/cm² at the tissue surface (Hamblin, 2017). Devices that fall below this range may not deliver a therapeutic dose within practical session times.

Build Quality and Safety Certifications

Electrical safety certifications (UL, ETL, or equivalent), proper grounding, EMF levels, and manufacturing quality are more relevant to consumer safety than the specific FDA pathway used.

Transparent Specifications

Companies that publish detailed specifications — including wavelength tolerance (±5 nm is acceptable), irradiance at multiple distances, beam angle, and LED specifications — demonstrate greater transparency than those hiding behind vague “FDA-cleared” claims.

The Bottom Line

FDA clearance is a useful baseline indicator that a device has passed safety testing, but it is widely misunderstood and frequently misrepresented in red light therapy marketing. No consumer red light therapy panel has received full FDA approval (PMA). The 510(k) clearance process demonstrates safety and substantial equivalence to existing devices — it does not demonstrate therapeutic efficacy.

When evaluating devices, look past regulatory claims to the underlying evidence: published clinical research, independent irradiance testing, wavelength verification, and transparent manufacturing standards. These factors tell you far more about a device’s likely effectiveness than its regulatory status.

For UK consumers specifically, FDA status is irrelevant to the UK regulatory framework. Look for CE marking under the Medical Device Regulation (not just the Low Voltage Directive), check ASA compliance of marketing claims, and prioritise devices with published clinical evidence supporting their specific wavelength and power output specifications.

References

Avci, P., Gupta, A., Sadasivam, M., et al. (2013). Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Seminars in Cutaneous Medicine and Surgery, 32(1), 41–52. PMID: 24049929
Hamblin, M.R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361. PMID: 28748217
Huang, Y.Y., Chen, A.C., Carroll, J.D., & Hamblin, M.R. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358–383. PMID: 20011653
US FDA. (2018). Classify Your Medical Device. FDA.gov. Retrieved from https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
US FDA. (2020). Premarket Notification 510(k). FDA.gov. Retrieved from https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
US FDA. (2021). General Wellness: Policy for Low Risk Devices — Guidance for Industry and Food and Drug Administration Staff. FDA.gov.
European Commission. (2017). Regulation (EU) 2017/745 on medical devices. Official Journal of the European Union.
MHRA. (2023). Regulating medical devices in the UK. GOV.UK.
Hamblin, M.R. & Huang, Y.Y. (2013). Handbook of Photomedicine. CRC Press. ISBN: 978-1439884690